1. Introduction
===============

Protein sequences of the human proteome as well as of a number of viral proteomes have become available in databanks, offering an opportunity for a thorough comparative analysis of their reciprocal inter-relationship(s). This area of inquiry is of special interest because of our persistent ignorance of the mechanisms at the basis of viral pathogenesis and virus--host interactions [@bib1], [@bib19]. To define the molecular structural determinants possibly involved in viral virulence and human susceptibility, we have undertaken a systematic analysis of a large set of viral proteomes searching for amino acid sequences shared with the human proteome.

Specifically, the study was designed to answer two main questions: (i) what is the quantitative dimension of short-peptide sequence sharing between viruses and human proteomes? (ii) How many human proteins harbor viral peptide modules? The two questions are of paramount importance in the context of autoimmune diseases. Indeed, it is a common belief that an autoimmune reaction is mostly caused by a host receiving an antigen that has amino acid homology/similarity with amino acid sequences in self-antigens of the host [@bib20]. This may result in the host immune system attacking the organs and tissues expressing the self-antigens with the shared sequences [@bib23]. In this context and given the sustained increase in the incidence of autoimmune diseases [@bib2], [@bib8], [@bib18], [@bib22], the mathematical quantification of peptide overlap extent between viruses and humans is essential to understand the role of structural viral similarity in the pathogenesis of autoimmunity. Here we report a virus versus human comparative screening that reveals a massive, indiscriminate, unexpected pentapeptide overlapping between viral and human proteomes.

2. Methods {#sec1}
==========

The viral proteomes analyzed in this study were downloaded from [www.ebi.ac.uk/genomes/virus.html](http://www.ebi.ac.uk/genomes/virus.html) and the human proteome obtained from UniProtKB (<http://www.ebi.ac.uk/integr8>). The human proteome originally contained 37,993 proteins at the time of download, but we filtered out (1) two viral contaminants (i.e. viral proteomes which were being expressed in human cells), and (2) duplicated sequences and fragments. After the filtering, we were left with a human proteome consisting of 36,103 unique proteins.

Similarity analyses were conducted on 30 viral proteomes for a total of 717 viral proteins, equal to 302,667 amino acids. A similarly sized control set of 30 human protein samples (for a total of 686 human proteins, equal to 302,520 amino acids) was analyzed for inter-human overlapping. More precisely, for each viral proteome size, we constructed an artificial human sub-proteome drawn from the human protein set. The proteins were selected at random without replacement, and assigned to an artificial sub-proteome at random. We kept adding human proteins to each artificial human sub-proteome until adding the next protein would have caused the total number of amino acids in the artificial sub-proteome to exceed to the number of amino acids in the corresponding viral proteome. This way we eliminated possible bias in the comparison. The 30 artificial sub-proteomes are random samplings of human proteins and represent cross-sections of all human proteins. The list of the human proteins forming the 30 artificial human sub-proteomes is detailed as Swiss-Prot entries in [Table 3](#tbl3){ref-type="table"}.

Sequence similarity analyses of each of the 30 viral proteomes (or the 30 artificial human sub-proteomes) to the human proteome were carried out using viral (or human) 5-mers sequentially overlapped by four residues. The scans were performed by custom programs written in C and utilizing suffix trees for efficiency [@bib6]. The viral or human proteins were manipulated and analyzed as follows. The entire viral (or human) proteome was decomposed *in silico* to a set of 5-mers (including all duplicates). A library of unique 5-mers for each virus or human proteome was then created by removing duplicates. Next, for each 5-mer in the library, the entire human proteome was searched for instances of the same 5-mer. Any such occurrence was termed an overlap. Cursory analyses (e.g. identification of unique overlapping 5-mers, counts of unique overlapping 5-mers, counts of duplications) were performed using LINIX/UNIX shell scripts and standard LINUX/UNIX utilities. Data were plotted and linear least-squares regression was performed to determine whether any linear relationships exist between the level of overlap and the size of viral (or control) proteomes. The same procedure was applied when longer amino acid sequences (esa-, epta-, octapeptides, etc.) were used as probes in the similarity analyses.

The similarity analysis for the artificial human sub-proteomes was performed as for the viral proteomes, with one modification. The modification is that all the proteins in the artificial proteome were removed from the comparison human proteome when the overlap determination was done. E.g., the artificial human sub-proteome 9 contains 12 human proteins selected from the original set of 36,103 proteins comprehensively forming the human proteome. These 12 proteins were removed from the comparison set prior to determining the overlap of artificial human sub-proteome 9 versus human; i.e. for artificial proteome 9, the overlap comparison was between 12 proteins in the artificial proteome and the remaining 36,091 human proteins. And similar for each of the other 29 artificial proteomes.

3. Results
==========

The viruses were chosen based on the following criteria: (1) known to be pathogenic to human; (2) of significant health impact (e.g. HCV, rhinovirus, HIV, mumps, measles, SARS, HPV, and polio); (2) phylogenetically different; (4) proteomes established to a significant degree of completeness. In addition, the viral proteomes were chosen to span a range of proteome sizes, with the smallest viral proteome being 1613 amino acids, the largest being 65,280 amino acids, and all the viral proteomes combined amounting to 302,667 amino acids. The viral proteomes are described in [Table 1](#tbl1){ref-type="table"} .Table 1Description of the viral proteomes analyzed for similarity to human proteinsTax IdVirus description and abbreviationAccessionProteinsaa10407Hepatitis B virus (HBV)[X51970](X51970)41,61310632JC polyomavirus (JCV)[J02226](J02226)51,62910798Human parvovirus B19[AF162273](AF162273)32,00612131Human rhinovirus 14 (HRV-14)[K02121](K02121)12,17912080Human poliovirus 1 (HPV-1)[AJ132961](AJ132961)12,209434309Saffold virus (SAF-V)[EF165067](EF165067)12,296333760Human papillomavirus type 16 (HPV16)[K02718](K02718)82,45211908Human T-cell leukemia virus 1 (HTLV-I)[U19949](U19949)62,58911103Hepatitis C virus (HCV)[AJ132997](AJ132997)13,01011041Rubella virus[AF188704](AF188704)23,17911089Yellow fever virus (YFV)[X03700](X03700)13,411307044West Nile virus (WNV)[AY842931](AY842931)13,43311676Human immunodeficiency virus 1 (HIV-1)[X01762](X01762)93,57111292Rabies virus[M31046](M31046)53,60011029Ross River virus (RRV)[M20162](M20162)23,73311709Human immunodeficiency virus 2 (HIV-2)[X05291](X05291)93,759162145Human metapneumovirus (hMPV)[AF371337](AF371337)94,16393838Influenza A virus (H5N1)[AF144300](AF144300)104,46711250Human respiratory syncytial virus (HRSV)[AF013254](AF013254)114,54011216Human parainfluenza virus 3 (HPIV3)[AB012132](AB012132)64,84211269Lake Victoria marburgvirus[Z12132](Z12132)74,84611161Mumps virus[AB040874](AB040874)84,97770149Measles virus[AY486084](AY486084)85,205186538Zaire virus[AF086833](AF086833)95,49363330Hendra virus[AF017149](AF017149)96,056321149SARS coronavirus (SARS-CoV)[AY864806](AY864806)1314,20910376Human herpesvirus 4 (HHV-4)[AY961628](AY961628)6934,91110368Human herpesvirus 6 (HHV-6)[X83413](X83413)11244,72010255Variola virus[X69198](X69198)19754,28910359Human herpesvirus 5 (HHV-5)[X17403](X17403)19065,280  Total71730,2667

As controls, we used 30 similarly sized protein sets drawn from the human proteome. In brief, we constructed 30 artificial sub-proteomes populated by proteins randomly selected without replacement from the human proteome. The constraints we used were that (1) the size of each artificial sub-proteome was to approximate the size of one of the viral proteomes, and (2) that the combined size of all the artificial proteomes was to approximate the combined size (in amino acids) of the viral proteomes. The 30 resultant artificial human sub-proteomes are described in [Table 2](#tbl2){ref-type="table"} . Table has four columns. The first is the artificial sub-proteome number. The second is the cumulative amino acid length of all the human proteins in that artificial sub-proteome. The third column is the cumulative amino acid length of the corresponding viral proteome. The fourth column is the number of human proteins in the artificial sub-proteome. For example, in our virus versus human analysis, information for hepatitis C virus (HCV) was used as follows. The virus has taxonomic ID 11103 and a proteome consisting of 3010 amino acids (see [Table 1](#tbl1){ref-type="table"}). Corresponding to this virus is the artificial human sub-proteome 9, which contains 12 human proteins which sum to a cumulative length of 2979 amino acids (i.e. just about the 3010 amino acids in the HCV proteome). And similar for each of the other 29 viral proteomes. The list of the human proteins forming the 30 artificial human sub-proteomes is detailed as Swiss-Prot entries in [Table 3](#tbl3){ref-type="table"} .Table 2Size descriptions of the 30 artificial human sub-proteomes used as controlsSub-proteome numberSize[a](#tbl2fn1){ref-type="table-fn"}Size[a](#tbl2fn1){ref-type="table-fn"} of the corresponding viral proteomeHuman proteins in the sub-proteome[b](#tbl2fn2){ref-type="table-fn"}11,5951,613721,6161,629431,9972,006942,1422,179952,1862,209662,2902,296772,4332,452482,5852,589792,9793,01012103,1563,1799113,3833,4118123,4273,43311133,5543,57111143,5943,60010153,7213,73312163,7593,75911174,1274,1638184,4374,46713194,5284,54013204,8274,8428214,8124,84611224,9454,97711235,2005,2058245,4925,49316256,0376,056152614,20314,209352734,89434,911722844,65544,720982954,26354,2891113065,68365,280130  Total302,520302,667686[^1][^2]Table 3List of the human proteins forming the 30 artificial human sub-proteomes used as controlsSub-proteomeProteins (Swiss-Prot accession number)1Q8NAW6; Q6IBU4; ARFP1_HUMAN; SODM_HUMAN; AIF1_HUMAN; MAGB1_HUMAN; Q6ZNA32Q6ZV29; Q86TW9; Q6UY40; Q9UI733Q70T18; Q5TCI3; GALT_HUMAN; LV1H_HUMAN; Q6ZUC0; Q9H0S3; TRXR2_HUMAN; Q5TG59; Q163674Q6NT40; Q5HY76; Q6EKI8; Q9BXM4; Q5T270; Q9UH93; Q6ZTB8; Q6ZSJ1; Q152175Q6IPM5; GPR39_HUMAN; Q6ZRY8; Q96QH2; Q4VXA4; S10AE_HUMAN6Q6ZQW9;Q96P35;Q6ZSD3;Q8WVE6; Q6ZN23; Q5H9B2; Q8IWT57Q59G50; Q3YL75; Q9BXX2; Q59GQ58DSCR8_HUMAN; PK3CA_HUMAN; Q6PDB3; Q8TBZ2; Q8TBU1; PHP14_HUMAN; Q9NR699LAP2A_HUMAN; O75100; Q8IYA8; Q9NWL9; Q6ZQN3; ZNF73_HUMAN; VEGFC_HUMAN; Q96FS0; Q5TBJ1; Q8IZX3; Q6AI09; Q96S9110Q5JV79; ATPK_HUMAN; Q6ZTT6; Q6IQ33; SYT9_HUMAN; Q5JXP8; Q71SF7; Q5SYF3; Q6PJ8011Q53ET8; Q12771; DDX31_HUMAN; Q66K28; GNA12_HUMAN; Q8TC57; DAX1_HUMAN; Q9BPY112Q6GTM5; PRS23_HUMAN; Q5VXF4; DIAP3_HUMAN; LRC32_HUMAN; Q5W0C9; Q8N4M7; TIM9_HUMAN; Q6ZSL6; Q5VZP2; CK051_HUMAN13Q6ZVP3; ADH4_HUMAN; Q9BUR5; CP1B1_HUMAN; Q8TEG4; Q86YC2; KRA63_HUMAN; Q5JYC0; Q6PJ81; Q9P1J6; Q8N5A814Q6IEE5; Q96CG3; Q59EI7; Q5TFG5; Q6NUM0; Q7L0X2; Q8N812; NLTP_HUMAN; Q29831; Q9NRI615GPR21_HUMAN; PDCL3_HUMAN; Q5JX47; Q9Y4Q5; Q86WR9; 1B47_HUMAN; TM9S4_HUMAN; HUNIN_HUMAN; Q6ZTA6; Q6P519; Q4G178; Q8WUE916ATF1_HUMAN; Q6ZSL8; Q5T0J3; Q8NB08; Q6MZW2; Q86T62; Q4G161; Q96HQ4; TSH3_HUMAN; Q6ZNA9; Q5TG3317OR5U1_HUMAN; Q9BRW6; FBX2_HUMAN; Q5TAE7; Q5T011; ELOV2_HUMAN; Q8NC43; Q5JR8918Q6ZRR8; Q5T435; Q6NUS8; CX033_HUMAN; ALG1_HUMAN; Q6ZUT0; Q86UH7; NCKX5_HUMAN; Q9BRY8; RT34_HUMAN; PODO_HUMAN; Q6ZNI2; Q6UXQ019Q6ZTL0; Q6H9L7; Q96I32; PIPNA_HUMAN; Q9H5L8; Q5W0W3; Q9UMD0; Q5T9C4; Q5VU34; Q8N996; TRI11_HUMAN; Q5T884; Q6VEP320VPS16_HUMAN; GLUC_HUMAN; Q5TI49; DAF_HUMAN; Q4G1H0; Q96KS6; Q5JX17; Q9H8F621Q5VZB4; DNAL4_HUMAN; Q6PD71; ATN1_HUMAN; LRMP_HUMAN; Q53FG3; OR2I1_HUMAN; Q6NVW6; DPEP3_HUMAN; Q96NA9; DCPS_HUMAN22GAK14_HUMAN; Q969I2; IL17D_HUMAN; Q6ZWP8; Q5JUX3; Q8NAN0; Q8NEC4; Q9NVL7; Q9H7G9; Q5SXN7; Q6ZVQ923Q5TAV5; Q4VHE5; CSMD3_HUMAN; Q6ZR54; Q86XE7; BCLW_HUMAN; SPR2B_HUMAN; Q5SUL124Q5T8C4; Q9H066; SO1B1_HUMAN; MLF2_HUMAN; Q6ZSJ6; Q3KRG0; Q9BWU4; Q5W0G7; Q8N9M6; Q5HYJ7; GP144_HUMAN; Q6ZUR8; Q9NX18; CAR10_HUMAN; Q6AI43; Q5VZL825Q562N1; Q71RA6; CF060_HUMAN; Q9NYJ1; NFE2_HUMAN; APEX1_HUMAN; Q9BRE8; Q8TEB3; KLF11_HUMAN; Q8NH86; Q71VA3; Q8N7V1; Q5T694; Q96EK9; PRGB_HUMAN26GP160_HUMAN; Q6ZTQ0; KPSH1_HUMAN; DAZ2_HUMAN; Q9UPD4; Q5TBP5; ZNF6_HUMAN; Q8N6V7; KGP1B_HUMAN; AMYP_HUMAN; KRA45_HUMAN; Q6PI78; Q68D85; TRI10_HUMAN; MAGC1_HUMAN; PRM2_HUMAN; STAC_HUMAN; P5I11_HUMAN; O19519; Q9Y6P1; LIPS_HUMAN; Q9NSQ0; Q5T5R8; Q2VU70; Q13901; Q9BWL2; Q5T4D3; Q5QPV6; Q9UHS2; Q9H6W3; Q8N930; Q6NSH2; Q2M2H8; Q5SR59; LY6E_HUMAN27Q8IY34; Q6XYE6; Q8IVW8; GCC1_HUMAN; LBH2_HUMAN; NEUU_HUMAN; Q71RC9; Q6P3S1; SC5A4_HUMAN; Q8WVS4; M3K2_HUMAN; Q4G186; Q572P5; CPNE8_HUMAN; ITM2B_HUMAN; Q6ZR04; Q6ZT02; TCP10_HUMAN; Q2HIZ2; Q86UC7; LRC24_HUMAN; Q3SX69; Q5JXA9; Q96CG5; Q5JZG9; MYO3B_HUMAN; Q15156; Q86TU2; Q9Y5L9; CG010_HUMAN; Q86VM9; Q5T932; Q8N7D3; SPG11_HUMAN; UB2V1_HUMAN; Q9Y2A3; BR44_HUMAN; Q8NBM8; Q6ZUE1; Q562S5; Q9GZU2; Q8N7G4; Q96DU8; Q8N7E6; Q14560; Q5SYX8; Q96KH8; Q96GK3; ATP5H_HUMAN; Q5TDQ5; SURF6_HUMAN; Q86TC9; Q3MI86; Q96NT9; Q7Z4A2; CCD70_HUMAN; STX1C_HUMAN; Q5VWX1; Q86TG5; CD016_HUMAN; Q59H22; Q6ZV55; PREX1_HUMAN; GOGA6_HUMAN; Q6IFP4; PRPS2_HUMAN; ZN337_HUMAN; Q6ZNV9; PUR9_HUMAN; UFC1_HUMAN; WBS16_HUMAN; Q8NCB228Q8N944; Q6ZSG9; KV1V_HUMAN; Q9Y2V8; CN102_HUMAN; ROM1_HUMAN; Q6P3X8; FMO5_HUMAN; CTLA4_HUMAN; Q8NB05; Q7Z444; Q6ZTQ4; NP1L4_HUMAN; Q8TCI8; GAK1_HUMAN; CD44_HUMAN; OLIG2_HUMAN; MK11_HUMAN; Q6X4T0; Q5H8A3; Q9BV16; HNF3G_HUMAN; CENPF_HUMAN; DLK_HUMAN; TF_HUMAN; BRSK1_HUMAN; NARG1_HUMAN; Q9HCY0; Q6ZTW1; PLAC8_HUMAN; ARSK_HUMAN; RBPSL_HUMAN; Q5VFH8; Q5SZI4; Q4G0S2; Q8N1P4; SPDYC_HUMAN; Q8N5X6; WBS22_HUMAN; Q9BR23; Q8N6P1; Q5TAH2; Q15301; CADH5_HUMAN; FKBP4_HUMAN; KCNE4_HUMAN; Q9Y6X4; Q5TE79; GPC5B_HUMAN; Q5T2T6; IL1F8_HUMAN; Q9BTD8; Q9NPQ3; SEC62_HUMAN; CCNH_HUMAN; Q6ZV71; OR2L5_HUMAN; Q9NWB6; Q5T7H5; Q8WUU2; Q9H9F7; RM49_HUMAN; RS11_HUMAN; Q9Y2A1; Q8N0U6; Q64FX8; S6A18_HUMAN; SYN3_HUMAN; Q496M3; Q6ZUE9; Q9P274; CTR2_HUMAN; Q69YS5; TKN1_HUMAN; Q3MIV1; Q59FM3; Q3ZM63; Q9H4G2; O43410; Q86TS7; Q6IAE4; NAF1_HUMAN; Q49AN6; TNNC2_HUMAN; TNMD_HUMAN; Q3SY69; RALA_HUMAN; CAN12_HUMAN; Q6ZR90; Q29RV7; Q2M3R7; Q6IN85; ATPG_HUMAN; TBC13_HUMAN; Q6ZNL3; Q6IV50; Q5JY14; Q6ZSV229Q6P2D1; Q9P1E4; RHPN2_HUMAN; Q8N657; Q5SUL4; DOCK3_HUMAN; PLOD1_HUMAN; SEL1L_HUMAN; O43379; Q6S382; STX4_HUMAN; O15281; CP2A6_HUMAN; Q9H2Q4; Q5TF13; Q6UX27; Q5JR60; Q59FA5; Q96LT2; K2C6B_HUMAN; GBRA2_HUMAN; CEBPG_HUMAN; DCBD2_HUMAN; CO6A2_HUMAN; IGF1R_HUMAN; Q8N139; Q86W07; JIP2_HUMAN; Q86SE5; Q6IF87; Q9H4T6; FBLN3_HUMAN; 1C06_HUMAN; MOB2_HUMAN; Q96RL5; Q9H5K0; NEUR4_HUMAN; Q8N1Y0; SPAG6_HUMAN; CRBB1_HUMAN; THNSL_HUMAN; Q9NW61; 9KD_HUMAN; Q92638; RCBT1_HUMAN; IMDH2_HUMAN; Q5VYN8; Q6UXJ7; Q2QGD7; Q96QS7; FHL3_HUMAN; Q59FX8; O00318; Q13584; ATRN_HUMAN; Q5VXJ0; O00172; Q8TB16; FBX47_HUMAN; Q59EY9; Q96D65; ABCC9_HUMAN; Q86T11; Q96SS4; Q6PCB0; Q7Z5Y7; Q6IA40; RB33A_HUMAN; TAAR2_HUMAN; ZNHI1_HUMAN; Q6MZG7; Q5VZ52; CI074_HUMAN; TMM28_HUMAN; Q53P42; RPA2_HUMAN; OR2G3_HUMAN; Q9H600; Q6PJ97; ZDH15_HUMAN; Q6RGF6; MTG8R_HUMAN; Q9H021; Q5D038; LAGE3_HUMAN; APMAP_HUMAN; Q6ISH0; Q9NXC2; PO3F2_HUMAN; Q96JN3; TNF15_HUMAN; Q71RE2; Q5V9X9; GSTM2_HUMAN; Q6ZUT7; Q13104; CTGE4_HUMAN; CASP2_HUMAN; Q5JVN7; Q96N29; Q8NF74; Q8NAC2; NDUB7_HUMAN; Q9UCY0; Q59GJ8; Q5JPH6; Q8TC08; Q5T2D2; Q5SXI0; Q9H3L6; Q5T2I930PIAS3_HUMAN; MP2K5_HUMAN; Q96AZ4; Q96LL3; SIA7A_HUMAN; Q86W69; Q6ZW49; ARSG_HUMAN; Q6ZVF5; Q5T0B9; OLR1_HUMAN; Q5T352; Q96PN1; AIM1_HUMAN; Q8NGL5; CCD37_HUMAN; O95082; Q5ST44; PTPRU_HUMAN; SIGL5_HUMAN; Q96K25; Q4VX17; Q8IUI0; CACB4_HUMAN; Q6PIG1; TIMD1_HUMAN; O75799; Q6ZT72; Q8N9J9; Q8TAJ0; Q6PJ41; UBR1_HUMAN; Q69YL4; Q3V6T2; PART1_HUMAN; BTNL3_HUMAN; Q5JTE1; Q8WYS4; Q96GA7; Q8WXV1; Q68D36; RNAS9_HUMAN; Q5VXV0; OR5P3_HUMAN; DKK4_HUMAN; Q9NT50; Q6S376; OR6K2_HUMAN; Q68DF6; EPC1_HUMAN; Q9BZH2; Q96MJ8; Q6ZVE4; Q8WYG5; ETV2_HUMAN; Q6UXY4; GPC5D_HUMAN; Q6U8A4; Q6ZMM8; Q5QPJ9; Q9BZU3; Q9UDD7; Q8TAV7; Q86VP5; O4F15_HUMAN; RB3GP_HUMAN; Q6ZSQ0; Q9P073; UBE2T_HUMAN; Q5JUP7; Q9P035; Q562W8; STAC3_HUMAN; Q5T7F9; Q6IPW8; SALL2_HUMAN; Q9H3F1; Q96M24; Q6ZRX3; Q2M3I1; Q9HBS1; Q5W5X9; Q8N5E1; OBP2A_HUMAN; Q6ZWA4; F102B_HUMAN; HES6_HUMAN; Q5JUU8; UTP20_HUMAN; TLR4_HUMAN; Q9UL85; Q496H8; HV2A_HUMAN; Q86VK9; Q8IV74; HXA9_HUMAN; Q68CS5; Q8TEH7; Q6ZNW8; TRPV1_HUMAN; Q8N3Q9; Q6P995; Q6EF02; FA47B_HUMAN; CI055_HUMAN; BAD_HUMAN; Q5T7E5; Q6LET9; Q5T6F2; Q5VWV2; PCD16_HUMAN; 3BHS7_HUMAN; CB013_HUMAN; Q59FA6; Q9H901; Q8N1Y8; Q9BVY2; Q6ZSI0; MYOTI_HUMAN; Q6P0L0; Q8IYC2; Q5SWJ3; SPDYA_HUMAN; Q9Y569; Q2QD09; Q6NXR2; Q5T3L7; Q8N2D3; Q5JR95; Q5TYV8

Sequence similarity analyses of each of the 30 viral proteomes (or the 30 human artificial sub-proteomes) to the human proteome were conducted using viral (or human) 5-mers sequentially overlapped by four residues. Basically, we used 5-mer sequences as probes to scan viral/human proteins against human proteome since pentapeptides are minimal structural units critically involved in biological/pathological interactions such as peptide--protein interaction and (auto)immune recognition ([@bib5], [@bib7], [@bib17], [@bib18], [@bib21] and further Refs. therein). Longer amino acid sequences (esa-, epta-, octapeptides, etc.) were used as additional probes to control the similarity pattern.

3.1. Quantitative analysis of the pentapeptide overlapping of viral versus human proteomes
------------------------------------------------------------------------------------------

The numerical values that define virus-to-human similarity level are reported in [Table 4](#tbl4){ref-type="table"} . The table documents that all of the 30 viral proteomes under analysis have high and wide pentapeptide overlapping to the human proteome. Only a limited number of viral pentamers are unique to the viruses, with no counterpart in the human proteome. The overlapping extent (in terms of percentage of unique viral 5-mers which occur in the human proteome, see column 6 in [Table 4](#tbl4){ref-type="table"}) is rarely less than 90%. That means that almost 90% of the viral pentamer peptides are widely, intensively and repeatedly scattered throughout the human proteome. Numerically, the viral versus human overlap is defined by 2,907,096 total matches. Also the viral overlapping distribution in the human proteome (as number of human proteins hosting viral 5-mers, column 5 in [Table 4](#tbl4){ref-type="table"}) is highest, being close to 100% with HHV-5 (i.e. HHV-5 pentamers are present in 35,708 human proteins out of the 36,103 ones which comprehensively form the human proteome).Table 4Viral versus human proteome overlap at the 5-mer levelVirus[a](#tbl4fn1){ref-type="table-fn"}123[b](#tbl4fn2){ref-type="table-fn"}4[b](#tbl4fn2){ref-type="table-fn"}56HBV1,5891,5971,46021,85213,11691.8JCV1,5311,6091,40422,48212,74091.7Human parvovirus B191,4431,9941,29021,48811,78389.3HRV-142,1732,1751,99323,76113,93691.7HPV-12,2032,2052,01623,43113,64891.5SAF-V2,2832,2872,09223,99513,94091.6HPV162,4192,4202,24528,94815,36192.8HTLV-I2,5632,5652,37344,04219,30392.5HCV3,0023,0062,75446,73120,26991.7Rubella virus3,1543,1712,89851,85920,40191.8YFV3,4003,4073,06943,24519,50590.2WNV3,4243,4293,08742,67019,70290.1HIV-13,0823,5352,79235,56817,48790.5Rabies virus3,5753,5803,31442,64319,58492.6RRV3,6223,6323,29742,42219,43691.0HIV-23,2853,7232,94945,72418,88889.7hMPV4,1204,1273,77952,91520,68891.7H5N14,4124,4274,03645,59920,11791.4HRSV4,4834,4964,11646,54019,87891.8HPIV34,8074,8184,41852,93421,13191.9Lake Victoria marburgvirus4,8084,8184,43967,05122,91592.3Mumps virus4,7864,9454,41761,01322,62792.2Measles virus4,9345,1734,56160,63823,04592.4Zaire virus4,8655,4574,48756,57722,23692.2Hendra virus5,2106,0204,81057,64622,64492.3SARS-CoV9,73914,1578,853108,63227,95790.9HHV-432,00934,63529,955531,94635,09293.5HHV-641,83444,27238,277467,20635,05791.4Variola virus52,01753,50147,180498,97035,03590.7HHV-561,00164,52056,300883,95235,70892.2  All[c](#tbl4fn3){ref-type="table-fn"}257,035299,701234,6912,907,096[^3][^4][^5][^6]

Given the ample literature documentation and research data in support of the critical role exerted by pentapeptide modules in cell biology as well in antigen/antibody immunorecognition ([@bib17], and Refs. therein), the data of [Table 4](#tbl4){ref-type="table"} are impressive. They become even more significant, if possible, when compared to the control data obtained for inter-human pentapeptide overlapping illustrated in [Table 5](#tbl5){ref-type="table"} . When 30 human artificial sub-proteomes were analyzed for pentapeptide overlapping to the entire human proteome, we obtained clear numerical evidence that the inter-human level of perfect 5-mer matching is of the same order of magnitude as the viral overlapping to human proteome detailed in [Table 4](#tbl4){ref-type="table"}, i.e. there are 3,713,010 inter-human versus 2,907,096 viral perfect 5-mer matches to the human proteome (see [Table 5](#tbl5){ref-type="table"}). Likewise, the number of human proteins involved in viral and inter-human overlaps is highest and practically identical in the numbers: human proteins are involved in the inter-human peptide overlapping for 697,373 times and in the viral versus human overlap for 633,229 times (see data from [Table 4](#tbl4){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}, respectively). This indicates a massive, repeated, acritical usage of the same pentapeptide blocks in viral and human proteomes.Table 5Human versus human proteome overlap at the 5-mer levelHuman sub-proteome[a](#tbl5fn1){ref-type="table-fn"}123[b](#tbl5fn2){ref-type="table-fn"}4[b](#tbl5fn2){ref-type="table-fn"}5611,5661,5671,49627,01414,38195.521,5981,6001,57626,35213,85098.631,9371,9561,88544,08717,22297.342,1002,1062,06430,02514,40098.252,0582,1621,98640,37417,65396.562,1312,2622,09862,56416,69898.472,2892,4172,22737,79617,30397.282,5562,5572,47533,38716,43996.892,8582,9312,72181,65020,10595.2103,0673,1203,04248,91819,06999.1113,3063,3513,19859,66621,56896.7123,3553,3833,27168,54922,69797.4133,4783,5103,37756,46921,22197.0143,5293,5543,41760,13821,49096.8153,6633,6733,59688,22922,45498.1163,6263,7153,54596,82722,06197.7174,0844,0953,95872,45123,64596.9184,3744,3854,11268,57924,05594.0194,4234,4764,29579,28324,47297.1204,7514,7954,73570,29622,68699.6214,6464,7684,555115,91626,28498.0224,8864,9014,85095,95925,34899.2235,0485,1684,74072,40023,45393.8245,4085,4285,144101,68626,71395.1255,9415,9775,841128,90427,75198.32613,14314,06312,700290,02232,68196.62733,28134,60632,460664,53935,18197.52842,68344,26341,535787,77835,37597.32951,86553,80450,075895,67235,48996.53062,21965,15660,5061,103,96235,62997.2  All[c](#tbl5fn3){ref-type="table-fn"}254,808299,749246,3223,713,010[^7][^8][^9][^10]

Plotting the viral 5-mer occurrences in the human proteome as a function of the viral proteome length (see data under [Table 4](#tbl4){ref-type="table"}, columns 2 and 4) produces the graph illustrated in [Fig. 1](#fig1){ref-type="fig"} . The following observations are worth noting: first, the level of viral overlaps to the human proteome is directly related to the length of the viral proteome by a linear relationship. The Pearson\'s correlation coefficient of the line is 0.97452, and represents an exceptionally strong linear relationship. Biologically, [Fig. 1](#fig1){ref-type="fig"} suggests that peptide motif sharing is a constant property of the viral proteomes, exclusively depending on the viral proteome length and with no relationship to other structural and/or pathogenic viral features. As a note of interest, it can be seen that HTLV-1, Rubella virus, and HCV present a number of overlaps to the human proteome above the expected number of overlaps predicted by the linear regression line. This indicates that the massive, repeated, acritical, usage of the same pentapeptide blocks in viral and human proteomes is even more accentuated in the case of HTLV-1, Rubella virus, and HCV.Fig. 1Viral 5-mer occurrences in the human proteome as a function of viral proteome length (see data under [Table 4](#tbl4){ref-type="table"}, columns 1 and 4). The symbols refer to: (\*), HTLV-1; (■), Rubella virus; (□), HCV; (+), other viral data point. The regression line (---) has an equation of *y* = 12.636*x* − 269.01, with a Pearson correlation coefficient (*r* value) of 0.97452. Both *x*- and *y*-axis are log scale.

3.2. Qualitative analysis of the pentapeptide overlapping of viral versus human proteomes
-----------------------------------------------------------------------------------------

To understand the overlap usage in entities so distant in the evolutionary time and so enormously different in the evolutionary history such as viruses and humans, we investigated the profile of viral motif distribution along the human proteome. Representative histograms are reported in [Fig. 2](#fig2){ref-type="fig"} . It can be seen that, independently of the virus size, the density of the viral 5-mer motif matches along the human proteome presents constant behavior, with virus portions endowed with high similarity alternating with portions scarcely represented in the human proteome. The same alternating behavior is shown by the histograms of inter-human overlapping by analyzing sub-proteomic sets of low, medium and large size ([Fig. 3](#fig3){ref-type="fig"} ).Fig. 2Viral versus human pentapeptide overlapping: similarity profile of low-, medium- and high-molecular weight viral proteomes to the human proteome. (A) Human parvovirus B19 (total aa: 2006); (B) SARS coronavirus BJ202 (total aa: 14,209); (C) Variola virus (total aa: 54,289).Fig. 3Human versus human pentapeptide overlapping: similarity profile of low-, medium- and large-sized artificial human sub-proteomes to the human proteome. Human sub-proteome set (see also [Table 2](#tbl2){ref-type="table"}): (A) 4 (total aa: 2142); (B) 26 (total aa: 14,203); (C) 29 (total aa: 54,263).

[Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"} confirm the commonality of pentapeptide block usage in viruses and humans and, more in general, document the existence of a basic structural platform in the protein world. As shown in [Table 6](#tbl6){ref-type="table"}, [Table 7](#tbl7){ref-type="table"} , the viral versus human overlapping is still remarkable by using viral esa- or eptapeptide sequences as probes.Table 6Viral versus human proteome overlap at the 6-mer levelVirus[a](#tbl6fn1){ref-type="table-fn"}123[b](#tbl6fn2){ref-type="table-fn"}4[b](#tbl6fn2){ref-type="table-fn"}56HBV1,5891,5934961,3941,22431.2JCV1,5271,6044611,4681,30130.1Human parvovirus B191,4421,9914311,3411,15029.8HRV-142,1742,1745791,4561,27026.6HPV-12,2042,2046191,4831,28828.0SAF-V2,2852,2856221,3921,28027.2HPV162,4122,4127392,0101,70330.6HTLV-I2,5592,5599673,2612,65837.7HCV3,0053,0051,0254,1953,09934.1Rubella virus3,1693,1691,1333,9183,11935.7YFV3,4063,4061,0052,6802,32229.5WNV3,4283,4289962,7442,36529.0HIV-13,0843,5269042,1351,83229.3Rabies virus3,5753,5751,1622,6352,19532.5RRV3,6133,6131,0692,7082,30129.5HIV-23,2833,7141,0064,6532,78030.6hMPV4,1174,1181,2453,2632,72030.2H5N14,4084,4171,1912,6742,33227.0HRSV4,4834,4851,2582,8472,45528.0HPIV34,8124,8121,3503,1942,72128.0Lake Victoria marburgvirus4,8114,8111,4975,6313,69531.1Mumps virus4,7874,9371,4633,7343,01730.5Measles virus4,9375,1651,5853,8233,20832.1Zaire virus4,8685,4481,4483,4882,92929.7Hendra virus5,2106,0111,5163,5383,03529.0SARS-CoV9,76714,1442,7049,4385,77027.6HHV-432,63434,56612,35850,01318,44537.8HHV-642,43244,16012,12635,79316,84728.5Variola virus53,13653,30413,87033,91116,16726.1HHV-563,11564,33021,87387,93123,62934.6  All[c](#tbl6fn3){ref-type="table-fn"}282,932298,96687,224259,655[^11][^12][^13][^14]Table 7Viral versus human proteome overlap at the 7-mer levelVirus[a](#tbl7fn1){ref-type="table-fn"}123[b](#tbl7fn2){ref-type="table-fn"}4[b](#tbl7fn2){ref-type="table-fn"}56HBV1,5861,58966102934.1JCV1,5231,599611081014.0Human parvovirus B191,4401,988491201043.4HRV-142,1732,173601181002.7HPV-12,2032,203691391233.1SAF-V2,2832,2833551511.5HPV162,4042,4041021631214.2HTLV-I2,5532,5531432832155.6HCV3,0043,0041294033694.2Rubella virus3,1673,1671713092825.3YFV3,4053,405961641532.8WNV3,4273,427961771702.8HIV-13,0793,517961631483.1Rabies virus3,5703,5701322081923.6RRV3,5953,5951191841693.3HIV-23,2783,7051211,3475353.6hMPV4,1094,1091232342122.9H5N14,4004,407961471392.1HRSV4,4744,4741061741622.3HPIV34,8064,8061261931702.6Lake Victoria marburgvirus4,8044,8041512812533.1Mumps virus4,7804,9291422142042.9Measles virus4,9315,1571582572443.2Zaire virus4,8615,4391412121962.9Hendra virus5,2046,0021262192032.4SARS-CoV9,75914,1312997906993.0HHV-432,67034,4971,8997,05034335.8HHV-642,42644,0481,2423,95422362.9Variola virus53,04453,1071,6382,76019163.0HHV-563,21664,1403,17616,74560305.0  All[c](#tbl7fn3){ref-type="table-fn"}284,918298,23210,86331,737[^15][^16][^17][^18]

3.3. Non-stochastic nature of the peptide overlapping between the viral and human proteomes under analysis
----------------------------------------------------------------------------------------------------------

The results illustrated in [Table 4](#tbl4){ref-type="table"}, [Table 6](#tbl6){ref-type="table"}, [Table 7](#tbl7){ref-type="table"} are indicative of a widespread peptide overlapping between viral proteins and the *Homo sapiens* proteome. In order to understand how the above reported data are mathematically governed, we explored the 30 viral proteomes and the 30 human sub-proteomes under analysis for the degree of internal redundancy and the viral versus human proteome overlapping at *n*-mer level (with *n* from 5 to 16 amino acids). The quantitative data we found are reported in [Table 8](#tbl8){ref-type="table"} listing three orders of data: (a) the number of unique occurrences of *n*-peptides in the 30 viral (or the 30 human) proteome samples; (b) the total number of occurrences (i.e. including multiple occurrences) of *n*-peptides in the 30 viral (or the 30 human) proteome samples; and c) the relative viral versus human *n*-peptide overlaps.Table 8Actual versus theoretical *n*-peptide occurrences in viral and human proteinsPeptide[a](#tbl8fn1){ref-type="table-fn"} (*n*-mer)Theoretical number[b](#tbl8fn2){ref-type="table-fn"} (×10^6^)Actual occurrences1234567891053.2257,035299,70142,666254,808299,74944,94142,64756,230234,6912,907,096664282,932298,96616,034286,515299,05812,5434,3945,08987,224259,65571,280284,918298,23213,314289,592298,3678,77545561710,86331,737825,600284,857297,49812,641289,744297,6767,932801631,6688,8059512,000284,497296,76412,267289,486296,9857,49930816564,0351010,240,000284,022296,03012,008289,096296,2947,19814274371,31111204,800,000283,494295,29611,802288,629295,6036,97489352661124,096,000,000282,926294,56211,636288,121294,9126,791552924491381,920,000,000282,341293,82911,488287,578294,2236,64533240316141,638,400,000,000281,735293,09611,361287,017293,5356,518112042541532,768,000,000,000281,116292,36311,247286,441292,8476,4060017120716655,360,000,000,000280,478291,63011,152285,842292,1606,31800148176[^19][^20][^21]

The first set of data, column 1 through 6 in [Table 8](#tbl8){ref-type="table"}, provides evidence that the numerical values for uniquely expressed *n-*peptides are always lower than the actual total values for *n*-peptide occurrences. This is remarkable in light of the enormously high number of potential *n*-peptides which theoretically are available. As an example, in face of the possible 3,200,000 pentamers, both the 30 viral proteomes and the 30 human sub-proteomes present a high degree of repetitiveness in their 5-mer composition. In fact, the 30 viral proteomes and the 30 human sub-proteomes are respectively formed by a total of 299,701 and 299,749 5-mers and, although there is the possibility of forming 3,200,000 different pentapeptides, these total 5-mers present 42,666 and 44,941 repeated pentapeptides, in the viral and human proteins, respectively. The intra-viral (or intra-human) peptide redundancy strikingly persists at higher *n*-mer level, despite the exponentially increasing numbers of theoretically possible *n*-mers. The intra-repetitiveness is mathematically quantified in [Table 8](#tbl8){ref-type="table"}, columns 3 and 6, for the 30 viral proteomes and the 30 human sub-proteomes, respectively.

The second set of data illustrates the overlapping at *n*-peptide level (with *n* from 5 to 16 amino acids) from the 30 viral proteomes versus the 30 human sub-proteomes ([Table 8](#tbl8){ref-type="table"}, columns 7 and 8). Again, we note that, although there is a potential pentapeptide reservoir amounting to 3,200,000, still 42,647 of unique viral pentapeptides (16.6% of the total) appear in the human proteins forming the 30 human sub-proteomes. When considering the total viral pentapeptides including multiple occurrences ([Table 8](#tbl8){ref-type="table"}, column 8), the viral contribution to the 30 human sub-proteomes raises to 56,230 pentamers. These repeated viral overlaps in the human proteins appear to further support the existence of a defined peptide repertoire which is utilized (even repeatedly) in protein composition. A similar observation holds in considering the viral peptide overlapping to the 30 human sub-proteomes at higher *n*-mer level ([Table 8](#tbl8){ref-type="table"}, columns 7 and 8).

Finally, the third set of data documents the overlaps at *n*-peptide level (with *n* from 5 to 16 amino acids) from the 30 viral proteomes versus the entire human proteome ([Table 8](#tbl8){ref-type="table"}, columns 9 and 10). It can be seen that, independently of the vastness of the human protein sample, the extent of the viral overlap is relevant, especially when considering that the human proteome has the possibility of drawing from an enormous number of potential theoretical *n*-peptides. For example, notwithstanding the astonishingly great repertoire of theoretical possible undecapeptides (that is: 204,800,000 millions), nonetheless eight viral overlaps (one of which even repeated) are present in the sub-proteomic human samples. The numbers raise to 352 and 661 (including multiple occurrences of the same 11-mer) when considering the viral 11-mer overlaps in the entire human proteome.

Our conclusion is that the mathematical redundancy present in the protein world is not stochastic (i.e. is not pure random chance), but rather reflects strong peptide usage bias since certain peptides are repeatedly used (and shared) in (and among) viral and human proteins. It seems that peptide usage in the protein world (and, consequently, the degree of similarity, repetition, overlapping) is not dictated by pure mathematical laws of distribution. Rather, powerful constraints appear to be at work by forcing the use of restricted platforms of *n*-mers and privileging the repeated usage of the chosen ones. Possibly, as anticipated by preliminary data from our labs (Kusalik et al., manuscript in preparation), these powerful constraints able to influence and favor specific *n*-mer synthesis might be found among physico-chemical factors such as hydrophobicity, residue bulkiness, Δ*G*° of peptide bond formation, plus biological factors such as codon bias.

4. Discussion
=============

The difference between biological entities such as viruses and cellular organisms is quite obvious when the functional roles of the proteins found in viruses and in cellular organisms are compared [@bib24]. On the other hand, according to the data we present here, this obvious difference disappears at the peptide phenetic level. The mathematical quantification of the widespread and high pentapeptide similarity between viral and human proteomes is surprising, raising fundamental questions. In particular, the ample viral-human peptide sharing is significant to (auto)immune phenomena as well as to evolutionary pathways.

Indeed, in the context of the physio(patho)logical relationships between viruses and humans, it is mandatory to observe that short-peptide motifs can exert a central role in cell adhesion, signal transduction, hormone activity, regulation of transcript expression, and enzyme activity [@bib3], [@bib9], [@bib10], [@bib14], [@bib15], [@bib17]. Likewise, the antigen-antibody recognition process can reductionistically be circumscribed to interacting modules of five amino acid residues which, therefore, appear to be sufficient structural immunological determinants ([@bib11], [@bib12], [@bib13], [@bib17] and Refs. therein). Consequently, we notice that the data shown here call into question the possibility of a direct causal association between virus--host sharing of amino acid motifs and incitement of autoimmune reactions [@bib20]. Indeed, the molecular mimicry hypothesis suggests that, when bacterial/viral agents share epitopes with a host\'s proteins, an immune response against the infectious agent may result in formation of cross-reacting antibodies that bind the shared epitopes on the normal cell and result in the auto-destruction of the cell. In the present case, the molecular mimicry hypothesis implies that viral infections should be a practically infinite source of autoimmunity diseases since this study demonstrates that viral 5-mer matches are disseminated throughout practically all the human proteome and each viral match is repeated almost more than 10 times (see [Table 4](#tbl4){ref-type="table"}). Consequently, autoimmune diseases should theoretically approach a 100% real incidence, since the 30 viruses we examined practically are more or less disseminated throughout the entire human species. Taking HCV as an example, we note that the virus versus human overlap analysis in [Table 4](#tbl4){ref-type="table"} produces the mathematical evidence that HCV (as well as HTLV-1 and Rubella virus) are even "more similar" to the human proteins than that expected by the linear regression relationship reported in [Fig. 3](#fig3){ref-type="fig"}. The data reinforce and add to our previous report on the sharing of numerous perfect exact matches between HCV and human proteomes [@bib16]. Since 2760 out of 3003 HCV 5-mers occur in the human proteome, the 46,731 occurrences include multiple/repeated matches in the human proteins. More exactly, each HCV 5-mer that overlaps with the human proteome are repeated an average of 16.5 times. Moreover, the 46,731 occurrences occur in 20,269 different human proteins ([Table 4](#tbl4){ref-type="table"}). That means that almost 60% of the 36,103 human proteins forming the *H. sapiens* proteome contain viral HCV pentamers. This datum is of cogent interest in the present worldwide advance of HCV infection, since it further excludes sequence similarity as a possible mechanism in HCV-associated autoimmunity phenomena and, at the same time, might address research towards new unexplored scenarios. These observations, of course, apply to almost all the viruses listed in [Table 1](#tbl1){ref-type="table"}.

When analyzed in the evolutionary context, the viral and human protein sets studied here yield a closely congruent overlapping pattern to the human proteome at the 5-mer level as well as at higher *n*-mer levels, indicating a common compositional mosaicism in viral and human proteins. The absence of specific phenetic *n*-mer clusterings in the viral versus human proteome (and *vice versa*) suggests a synergetic platform of development of non-equilibrium systems which can be traced back to the Prigoginian model rather than to the Darwinian evolutionary scheme, where harmful protein sequences are "selectively removed" whereas neutral or useful peptides are left alone. *De facto*, it seems that viruses and mammalians have drawn and draw from a common ancient melting pot of short-peptide modules in building up their proteomes, either simple or complex. Indeed, it seems that human evolution has paid very little attention to a peptide motif being viral or not. The reconstruction of the informational network relating all living organisms might be helped by an integration with the present data which recall a time when the totality of life on Earth was a simple heterogeneous community that shared only the ability to synthesize proteins with a ribosomal machine and that freely exchanged genetic material [@bib4].

[^1]: Amino acid number.

[^2]: Composed by set of human proteins as detailed under Section [2](#sec1){ref-type="sec"} and in [Table 3](#tbl3){ref-type="table"}.

[^3]: Human proteome formed by 36,103 proteins and 15,771,565 occurrences of 2,388,563 unique 5-mers. Column number refers to: (1) unique 5-mers in the viral proteome; (2) total number of 5-mers in the viral proteome (including multiple occurrences); (3) unique viral 5-mers occurring in the human proteome; (4) viral overlap occurrences in the human proteome (including multiple occurrences); (5) number of human proteins involved in overlap; (6) % of unique viral 5-mers which occur in the human proteome (i.e. 100 × column 3/column 1).

[^4]: Abbreviations as in [Table 1](#tbl1){ref-type="table"}.

[^5]: The results of linear regression analysis between columns 1 and 3, and 1 and 4 are: column 3 = 0.91811 × column 1 − 1.2272 (*r* = 0.99993). Column 4 = 12.636 × column 1 − 269.01 (*r* = 0.97452).

[^6]: Obtained by combining all 30 viral proteomes into one viral proteome, and then computing the overlap with the entire human proteome.

[^7]: All 30 artificial human sub-proteomes constitute 686 proteins and are numbered from 1 to 30. The comparison human proteome contained 36,103 proteins and 15,771,565 occurrences of 2,388,563 unique 5-mers. Column number refers to: (1) unique 5-mers in the artificial sub-proteome; (2) total number of 5-mers in the artificial sub-proteome (including multiple occurrences); (3) unique 5-mers from the artificial sub-proteome occurring in the human proteome; (4) occurrences in the human proteome of 5-mers from artificial sub-proteome (including multiple occurrences); (5) number of human proteins in the human proteome involved in overlap; (6) % of unique 5-mers from the artificial sub-proteome which occur in the human proteome (i.e. 100 × column 3/column 1).

[^8]: Analogous to viral proteomes in size (see [Table 1](#tbl1){ref-type="table"}), and composed by set of human proteins as detailed in [Table 3](#tbl3){ref-type="table"}.

[^9]: The results of linear regression analysis between columns 1 and 3, and 1 and 4 are: column 3 = 0.97083 × column 1 + 0.76628 (*r* = 0.99998). Column 4 = 17.921 × column 1 + 6278.6 (*r* = 0.99719).

[^10]: Obtained by combining all 30 human sub-proteomes into one sub-proteome, and then computing the overlap with the entire original human proteome minus the proteins in the combined sub-proteomes.

[^11]: Human proteome formed by 36,103 proteins and 15,734,725 occurrences of 8,247,275 unique 6-mers. Column number refers to: (1) unique 6-mers in the viral proteome; (2) total number of 6-mers in the viral proteome (including multiple occurrences); (3) unique viral 6-mers occurring in the human proteome; (4) viral overlap occurrences in the human proteome (including multiple occurrences); (5) number of human proteins involved in overlap; (6) % of unique viral 6-mers which occur in the human proteome (i.e. 100 × column 3/column 1).

[^12]: Abbreviations as in [Table 1](#tbl1){ref-type="table"}.

[^13]: The results of linear regression analysis between columns 1 and 3, and 1 and 4 are: column 3 = 0.31426 × column 1 − 42.237 (*r* = 0.98762). Column 4 = 1.0972 × column 1 − 877.68 (*r* = 0.93373).

[^14]: Obtained by combining all 30 viral proteomes into one viral proteome, and then computing the overlap with the entire human proteome.

[^15]: Human proteome formed by 36,103 proteins and 15,697,964 occurrences of 10,431,975 unique 7-mers. Column number refers to: (1) unique 7-mers in the viral proteome; (2) total number of 7-mers in the viral proteome (including multiple occurrences); (3) unique viral 7-mers occurring in the human proteome; (4) viral overlap occurrences in the human proteome (including multiple occurrences); (5) number of human proteins involved in overlap; (6) % of unique viral 7-mers which occur in the human proteome (i.e. 100 × column 3/column 1).

[^16]: Abbreviations as in [Table 1](#tbl1){ref-type="table"}.

[^17]: The results of linear regression analysis between columns 1 and 3, and 1 and 4 are: column 3 = 0.042176 × column 1 − 36.723 (*r* = 0.95637); column 4 = 0.17329 × column 1 − 410.74 (*r* = 0.84397).

[^18]: Obtained by combining all 30 viral proteomes into one viral proteome, and then computing the overlap with the entire human proteome.

[^19]: Column number: (1) actual unique *n*-mers in the 30 viral proteomes; (2) actual *n*-mers in the 30 viral proteomes (including multiple occurrences); (3) number of repeated *n*-mers in the 30 viral proteomes; (4) actual unique *n*-mers in the 30 human sub-proteomes; (5) actual *n*-mers in the 30 human sub-proteomes (including multiple occurrences); (6) number of repeated *n*-mers in the 30 human sub-proteomes; (7) unique viral *n*-mers overlaps in the 30 human sub-proteomes; (8) total viral *n*-mers overlaps in the 30 human sub-proteomes (including multiple occurrences); (9) unique viral *n*-mers overlaps in the human proteome; (10) total viral *n*-mers overlaps in the human proteome (including multiple occurrences).

[^20]: Peptide length, with *n* from 5 to 16 amino acids.

[^21]: The number of possible amino acid combinations is given by 20^*n*^.
